{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:49:20Z","timestamp":1790282960102,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K09729"],"award-info":[{"award-number":["23K09729"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"DOI":"10.1186\/s13561-025-00710-y","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:54:24Z","timestamp":1766134464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Societal cost-of-illness analysis of self-injection of biologics for patients with rheumatoid arthritis in Japan using claims, surveys, and national statistics"],"prefix":"10.1186","volume":"15","author":[{"given":"Kazuhiko","family":"Takahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"10416","key":"710_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(23)01525-8.","journal-title":"Lancet"},{"issue":"12","key":"710_CR2","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/1756-185X.13974","volume":"23","author":"A Nakajima","year":"2020","unstructured":"Nakajima A, Sakai R, Inoue E, Harigai M. Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National database of health insurance claims and specific health checkups of Japan. Int J Rheum Dis. 2020;23(12):1676\u201384. https:\/\/doi.org\/10.1111\/1756-185X.13974.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"710_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","volume":"30","author":"H Yamanaka","year":"2020","unstructured":"Yamanaka H, Tanaka E, Nakajima A, Furuya T, Ikari K, Taniguchi A, Inoue E, Harigai M. A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options. Mod Rheumatol. 2020;30(1):1\u20136. https:\/\/doi.org\/10.1080\/14397595.2019.1660028.","journal-title":"Mod Rheumatol"},{"issue":"10","key":"710_CR4","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.23512","volume":"70","author":"A Hresko","year":"2018","unstructured":"Hresko A, Lin TC, Solomon DH. Medical care costs associated with rheumatoid arthritis in the US: A systematic literature review and meta-analysis. Arthritis Care Res (Hoboken). 2018;70(10):1431\u20138. https:\/\/doi.org\/10.1002\/acr.23512.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"710_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10165-009-0236-3","volume":"20","author":"E Tanaka","year":"2010","unstructured":"Tanaka E, Inoue E, Mannalithara A, Bennett M, Kamitsuji S, Taniguchi A, et al. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in japan: a large prospective observational cohort study. Mod Rheumatol. 2010;20(1):46\u201353. https:\/\/doi.org\/10.1007\/s10165-009-0236-3.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"710_CR6","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1136\/ard.2004.033977","volume":"64","author":"SM Verstappen","year":"2005","unstructured":"Verstappen SM, Boonen A, Verkleij H, Bijlsma JW, Buskens E, Jacobs JW, et al. Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis. 2005;64(12):1754\u201360. https:\/\/doi.org\/10.1136\/ard.2004.033977.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"710_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/10717544.2019.1587043","volume":"26","author":"BJF van den Bemt","year":"2019","unstructured":"van den Bemt BJF, Gettings L, Doma\u0144ska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384\u201392. https:\/\/doi.org\/10.1080\/10717544.2019.1587043.","journal-title":"Drug Deliv"},{"issue":"11","key":"710_CR8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/apt.16927","volume":"55","author":"V Bergqvist","year":"2022","unstructured":"Bergqvist V, Holmgren J, Klintman D, Marsal J. Real-world data on switching from intravenous to subcutaneous Vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(11):1389\u2013401. https:\/\/doi.org\/10.1111\/apt.16927.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"710_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.contraception.2018.07.137","volume":"98","author":"L Di Giorgio","year":"2018","unstructured":"Di Giorgio L, Mvundura M, Tumusiime J, Morozoff C, Cover J, Drake JK. Is contraceptive self-injection cost-effective compared to contraceptive injections from facility-based health workers? Evidence from Uganda. Contraception. 2018;98(5):396\u2013404. https:\/\/doi.org\/10.1016\/j.contraception.2018.07.137.","journal-title":"Contraception"},{"issue":"1","key":"710_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1477-7525-9-2","volume":"9","author":"D Keininger","year":"2011","unstructured":"Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection assessment questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9(1):2. https:\/\/doi.org\/10.1186\/1477-7525-9-2.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"710_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12913-025-12908-1","volume":"25","author":"K Takahata","year":"2025","unstructured":"Takahata K, Maeda Y, Tanaka E, Sakai R, Akazawa M. Health economic evaluation of self-injection of biologics in patients with rheumatoid arthritis using a Japanese real-world web-based survey. BMC Health Serv Res. 2025;25(1):730. https:\/\/doi.org\/10.1186\/s12913-025-12908-1.","journal-title":"BMC Health Serv Res"},{"key":"710_CR12","doi-asserted-by":"publisher","unstructured":"Takahata K, Akutsu S, Tanaka E, Sakai R, Akazawa M. Economic impact of self-injected biologics for rheumatoid arthritis in japan: a propensity score-matched analysis from a public healthcare payer\u2019s perspective. Value Health Reg Issues. 2025 Oct;23:53101511. https:\/\/doi.org\/10.1016\/j.vhri.2025.101511.","DOI":"10.1016\/j.vhri.2025.101511"},{"issue":"2","key":"710_CR13","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1111\/1346-8138.16691","volume":"50","author":"H Saeki","year":"2023","unstructured":"Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, et al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 2023;50(2):e41\u201368. https:\/\/doi.org\/10.1111\/1346-8138.16691.","journal-title":"J Dermatol"},{"key":"710_CR14","unstructured":"Ministry of Health, Labour and Welfare (MHLW). Requirements and Precautions for Home Self-Administration of Injectable Medications under the Japanese Health Insurance System. 2022. https:\/\/www.mhlw.go.jp\/content\/12404000\/001010502.pdf. Accessed 2 Sep 2025."},{"key":"710_CR15","doi-asserted-by":"publisher","unstructured":"Akutsu S, Takahata K, Sakai R, Akazawa M. Comparison of the risk of hospitalized infections between self-injecting and non-self-injecting biologics in patients with rheumatoid arthritis. Mod Rheumatol. 2025;roaf086. https:\/\/doi.org\/10.1093\/mr\/roaf086.","DOI":"10.1093\/mr\/roaf086"},{"issue":"8","key":"710_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","volume":"29","author":"A Larg","year":"2011","unstructured":"Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. PharmacoEconomics. 2011;29(8):653\u201371. https:\/\/doi.org\/10.2165\/11588380-000000000-00000.","journal-title":"PharmacoEconomics"},{"key":"710_CR17","doi-asserted-by":"crossref","unstructured":"Gold MRSJ, Russell LB, Weinstein MC, editors. Cost-Effectiveness in health and medicine. Oxford University Press; 1996.","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"710_CR18","unstructured":"DeSC Healthcare, Inc. https:\/\/desc-hc.co.jp\/company. Accessed 2 Sep 2025."},{"issue":"1","key":"710_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14961\/cra.33.6","volume":"33","author":"A Nakajima","year":"2021","unstructured":"Nakajima A. Medical practice and issues of rheumatoid arthritis from the viewpoint of big database research. Clin Rheumatol Rel Res. 2021;33(1):6\u201313. https:\/\/doi.org\/10.14961\/cra.33.6.","journal-title":"Clin Rheumatol Rel Res"},{"key":"710_CR20","unstructured":"Ministry of Health, Labour and Welfare (MHLW). Various Information of Medical Fee. https:\/\/shinryohoshu.mhlw.go.jp\/shinryohoshu\/. Accessed 2 Sep 2025."},{"key":"710_CR21","unstructured":"Medilead. Inc. Research Panel MHP (Medilead Healthcare Panel). https:\/\/www.medi-l.com\/. Accessed 2 Sep 2025."},{"issue":"12","key":"710_CR22","first-page":"949","volume":"41","author":"H Yamaguchi","year":"2020","unstructured":"Yamaguchi H, Iwasaki K, Shoji A, Kokubo K, Igarashi A. Health-related quality of life (QoL) in Japanese patients with cancer: a large-scale questionnaire survey using EQ-5D-5L. Ther Res. 2020;41(12):949\u201355.","journal-title":"Ther Res"},{"issue":"1","key":"710_CR23","first-page":"17","volume":"49","author":"H Masaki","year":"2021","unstructured":"Masaki H, Ishisaki S, Uenishi T, Kokubo K, Igarashi A. A survey of the impact of COVID\u201319 on the visiting frequency of Japanese patients with Gastrointestinal diseases. Jpn Pharmacol Ther. 2021;49(1):17\u201339.","journal-title":"Jpn Pharmacol Ther"},{"issue":"6","key":"710_CR24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/art.11465","volume":"49","author":"Y Matsuda","year":"2003","unstructured":"Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford health assessment questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49(6):784\u20138. https:\/\/doi.org\/10.1002\/art.11465.","journal-title":"Arthritis Rheum"},{"key":"710_CR25","unstructured":"Ministry of Health. Labour and Welfare (MHLW). the 2023 Basic Survey on Wage Structure. https:\/\/www.mhlw.go.jp\/toukei\/itiran\/roudou\/chingin\/kouzou\/z2023\/index.html. Accessed 2 Sep 2025."},{"key":"710_CR26","unstructured":"Ministry of Health, Labour and Welfare (MHLW). Overview of the 2020 Patient Survey (Preliminary Figures). https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jyuryo\/20\/dl\/gaikyo-all-g.pdf. Accessed 2 Sep 2025."},{"issue":"2","key":"710_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/s0167-6296(99)00032-6","volume":"19","author":"TE Getzen","year":"2000","unstructured":"Getzen TE. Health care is an individual necessity and a National luxury: applying multilevel decision models to the analysis of health care expenditures. J Health Econ. 2000;19(2):259\u201370. https:\/\/doi.org\/10.1016\/s0167-6296(99)00032-6.","journal-title":"J Health Econ"},{"key":"710_CR28","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.2283686","author":"TE Getzen","year":"2013","unstructured":"Getzen TE. Modeling medical cost trends for advancing age in the long run. SSRN Electron J. 2013. https:\/\/doi.org\/10.2139\/ssrn.2283686.","journal-title":"SSRN Electron J"},{"key":"710_CR29","unstructured":"Actuaries So. Getzen Model of Long-Run Medical Cost Trends Update for 2021\u20132030+. Schaumburg, IL: Society of Actuaries. Oct 2020. https:\/\/www.soa.org\/4a9eb0\/globalassets\/assets\/files\/resources\/research-report\/2020\/getzen-model-update-2021-2030.pdf. Accessed 2 Sep 2025."},{"key":"710_CR30","unstructured":"Ministry of Health, Labour and Welfare (MHLW). Basic Policy on the 2024 Revision of Medical Service Fees 2024. https:\/\/www.mhlw.go.jp\/stf\/newpage_36801.html. Accessed 2 Sep 2025."},{"key":"710_CR31","unstructured":"Ministry of Health, Labour and Welfare (MHLW). Overview of the FY2024 Drug Pricing System Reform. https:\/\/www.mhlw.go.jp\/content\/12400000\/001238906.pdf. Accessed 2 Sep 2025."},{"issue":"4","key":"710_CR32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/hec.1599","volume":"20","author":"PH van Baal","year":"2011","unstructured":"van Baal PH, Feenstra TL, Polder JJ, Hoogenveen RT, Brouwer WB. Economic evaluation and the postponement of health care costs. Health Econ. 2011;20(4):432\u201345. https:\/\/doi.org\/10.1002\/hec.1599.","journal-title":"Health Econ"},{"issue":"5","key":"710_CR33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691\u2013705. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04167.x.","journal-title":"Br J Clin Pharmacol"},{"key":"710_CR34","doi-asserted-by":"publisher","first-page":"A358","DOI":"10.1136\/annrheumdis-2013-eular.1100","volume":"72","author":"K Kumar","year":"2013","unstructured":"Kumar K, Raza K, Gill P, Greenfield S. THU0572\u2005adherence to disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis: A qualitative study in two ethnic groups. Ann Rheum Dis. 2013;72:A358. https:\/\/doi.org\/10.1136\/annrheumdis-2013-eular.1100.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"710_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/qhc.13.3.172","volume":"13","author":"N Barber","year":"2004","unstructured":"Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients\u2019 problems with new medication for chronic conditions. Qual Saf Health Care. 2004;13(3):172\u20135. https:\/\/doi.org\/10.1136\/qhc.13.3.172.","journal-title":"Qual Saf Health Care"},{"key":"710_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fphar.2013.00091","volume":"4","author":"P Kardas","year":"2013","unstructured":"Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91. https:\/\/doi.org\/10.3389\/fphar.2013.00091.","journal-title":"Front Pharmacol"},{"issue":"6","key":"710_CR37","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jbspin.2004.01.003","volume":"71","author":"AC Rat","year":"2004","unstructured":"Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine. 2004;71(6):518\u201324. https:\/\/doi.org\/10.1016\/j.jbspin.2004.01.003.","journal-title":"Joint Bone Spine"},{"key":"710_CR38","unstructured":"Cabinet Office GoJ. Annual Report on the Aging Society: 2025 (White Paper on Aging Society). 2025. https:\/\/www8.cao.go.jp\/kourei\/whitepaper\/index-w.html. Accessed 2 Sep 2025."},{"key":"710_CR39","unstructured":"Ministry of Health, Labour and Welfare (MHLW). Measures to Ensure Employment Opportunities Up to the Age of 70 (in accordance with the revised Act on Stabilization of Employment of Elderly Persons). 2021. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/koyou_roudou\/koyou\/koureisha\/topics\/tp120903-1_00001.html. Accessed 2 Sep 2025."},{"issue":"4","key":"710_CR40","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/1756-185X.13803","volume":"23","author":"F Salaffi","year":"2020","unstructured":"Salaffi F, Di Carlo M, Farah S, Carotti M. Adherence to subcutaneous anti-TNF\u03b1 agents in patients with rheumatoid arthritis is largely influenced by pain and skin sensations at the injection site. Int J Rheum Dis. 2020;23(4):480\u20137. https:\/\/doi.org\/10.1111\/1756-185X.13803.","journal-title":"Int J Rheum Dis"},{"key":"710_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/OARRR.S523778","volume":"17","author":"A Mamasaidov","year":"2025","unstructured":"Mamasaidov A, Sakibaev K, Zhumabaeva S, Isakov U, Eshbaeva CA, Abdyllaev J, et al. Impact of biological therapies on quality of life in rheumatoid arthritis: A narrative review. Open Access Rheumatol. 2025;17:73\u201386. https:\/\/doi.org\/10.2147\/OARRR.S523778.","journal-title":"Open Access Rheumatol"},{"key":"710_CR42","unstructured":"Japan College of Rheumatology. The 2024 Japanese College of Rheumatology Guidelines for the Management of Rheumatoid Arthritis2024."}],"updated-by":[{"DOI":"10.1186\/s13561-026-00816-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000}}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-025-00710-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-025-00710-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-025-00710-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:52:09Z","timestamp":1790239929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13561-025-00710-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["710"],"URL":"https:\/\/doi.org\/10.1186\/s13561-025-00710-y","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article was revised: the authors identified several errors in the article. Key numerical results are missing in Abstract (Results); the numbering labels ([1], [2], [3]) under section \"Data sources and study population\" were incorrectly treated as reference citations; the reference (25) citation in section \u201cOfficial statistical data\u201d was incorrectly treated as normal number that resulted to incorrect numbering of references; unconverted characters in Table 2; and a portion of Discussion text appears to have been inadvertently included within the Results section.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13561-026-00816-x","URL":"https:\/\/doi.org\/10.1186\/s13561-026-00816-x","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Meiji Pharmaceutical University Research Ethics Committee in March 2022 (Approval No. 202144). The study adhered to the principles for ethical research outlined in the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KT is an employee of Kyowa Kirin Co., Ltd. and has received tuition support for part of his doctoral degree program from the company. ET has received lecture fees or consulting fees from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., GlaxoSmithKline K.K., Mikasa Seiyaku co., Ltd., Mitsubishi Tanabe Pharma Co., Nichi-Iko Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Japan Inc, Sandoz K.K., Taisho Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Towa Pharmaceutical Co., Ltd., UCB Japan Co. Ltd. and Viatris Inc. ET received research funding from Pfizer Inc. RS has received consulting fees from Nippon Kayaku Co., Ltd.\u00a0MA received lectures and consulting fees from Astellas Pharma Inc., Mitsubishi Tanabe Pharma Co., GlaxoSmithKline K.K., and Janssen Pharmaceutical K.K. Peer reviewers for this manuscript have no relevant financial or other relationships to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"106"}}